Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.2K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

2.2K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.2K
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

1.2K
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
1.2K
Depression: Overview01:18

Depression: Overview

1.2K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The relationship between maternal experiences of abuse and maternal sensitivity in early mother-infant interactions.

Journal of reproductive and infant psychology·2026
Same author

A qualitative investigation of young people's experiences and views of Early Support Hubs across England.

PloS one·2026
Same author

Can whole-family interventions target violence and parenting in families experiencing domestic violence and abuse? A longitudinal study of the For Baby's Sake programme.

BMC psychology·2026
Same author

Maternal glycaemia and child educational attainment at age 5 in the Born in Bradford cohort.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Barriers to accessing perinatal mental health services in ethnically diverse women in the UK.

BMC psychiatry·2026
Same author

Visual content and thematic analyses of images shared on social media before and after episodes of self-harm in a UK clinical youth sample.

BMJ open·2026

関連する実験動画

Updated: Apr 12, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.9K

産後うつ病に対する抗うつ剤治療

Emma Molyneaux1, Kylee Trevillion1, Louise M Howard1

  • 1Health Service and Population Research Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.

JAMA
|May 20, 2015
PubMed
まとめ

セロトニン再吸収阻害剤 (SSRI) は,プラセボと比較して,産後うつ病に対する応答と寛解を改善します. しかし,重症症例や心理療法との比較に関するデータは依然として不十分です.

科学分野:

  • 生殖精神医学は,生殖に関する精神医学である.
  • 生後期の精神保健について
  • 薬理学的介入 薬理学的介入

背景:

  • 産後うつ病 (PND) は,かなりの数の母親に影響します.
  • PNDの効果的な治療法は,母と乳児の健康にとって極めて重要です.
  • PNDにおける抗うつ薬の有効性に関する現在の証拠は,合成を必要とする.

研究 の 目的:

  • 産後うつ病の女性における抗うつ剤の使用とアウトカムとの関連性を評価する.
  • プラセボに対する抗うつ薬の効果と,PNDに対する心理的介入を比較する.

主な方法:

  • ランダム化制御試験の体系的レビューとメタ解析.
  • 抗うつ剤とプラセボを比較した研究を含む.
  • 主なアウトカムとして応答率と寛解率の評価.

主要な成果:

  • 選択的セロトニン再吸収阻害剤 (SSRI) は,プラセボと比較して有意に優れた応答と寛解率を示しました.
  • 重度のPNDまたは自殺念頭については,限られたデータが存在します.
  • 抗うつ剤と心理学的介入を比較するための証拠は不十分である.

さらに関連する動画

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

738
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.7K

関連する実験動画

Last Updated: Apr 12, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.9K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

738
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.7K

結論:

  • SSRIは,PNDの女性の応答と寛解を改善するのに有効です.
  • 重度のPNDおよび心理療法との比較効果については,さらなる研究が必要である.
  • 抗うつ薬は,中程度のPNDの有効な選択肢です.